ming du

Dr. ming du


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 January 2026 in Phycology
Verified
Journal Article
Open access
PDF file
WSWentao Sun
Wentao Sun
MDming du
ming du
GSGuoming Shen
Guoming Shen
DLDongming Lai
Dongming Lai
Jiangxin WangJiangxin Wang
Jiangxin Wang
Microalgae are sustainable sources of bioactive compounds with broad hepato-protective potential. This review synthesizes evidence for five major classes—carotenoids such as astaxanthin and fucoxanthin, polysaccharides such as paramylon and fucoidan, phycobiliproteins such as phycocyanin, omega-3 fatty acids, and phenolic extracts—linking their actions to key liver injury mechanisms. Preclinically, these compounds enhance antioxidant defenses, improve mitochondrial function, suppress inflammatory signaling, regulate lipid metabolism, modulate the gut–liver axis, and inhibit hepatic stellate cell activation, thereby attenuating fibrosis. Consistent benefits are observed in models of non-alcoholic and alcoholic fatty liver disease, drug-induced injury, ischemia–reperfusion, and fibrosis, with marked improvements in liver enzymes, oxidative stress, inflammation, steatosis, and collagen deposition. Emerging evidence also highlights their roles in regulating endoplasmic reticulum stress and ferroptosis. Despite their promise, translational challenges include compositional variability, a lack of standardized quality control, limited safety data, and few rigorous human trials. To address these challenges, we propose a framework integrating multi-omics and AI-assisted strain selection with specification-driven quality control and formulation-aware designs—such as lipid carriers for carotenoids or rational combinations like fucoxanthin with low-molecular-weight fucoidan. Future priorities include composition-defined randomized controlled trials in non-alcoholic fatty liver disease, alcoholic liver disease, and drug-induced liver injury; harmonized material specifications; and multi-constituent interventions that synergistically target oxidative, inflammatory, metabolic, and fibrotic pathways.


6 August 2026 in Phycology
Verified
Journal Article
Open access
PDF file
JLJing Liu
Jing Liu
LLLeshi Li
Leshi Li
YYYan Yan
Yan Yan
MDming du
ming du
Jiangxin WangJiangxin Wang
Jiangxin Wang
The pet food industry is undergoing a significant transformation, driven by the growing trend of companion animal humanization and increasing concerns over the environmental sustainability of conventional protein and lipid sources. Consumers now seek diets that not only meet basic nutritional requirements but also offer preventive health benefits. Microalgae, including Arthrospira (Spirulina, a kind of cyanobacterium), Chlorella, Schizochytrium, and Euglena gracilis, have emerged as versatile biological platforms capable of addressing both functional and sustainability challenges. These microorganisms produce high-quality proteins, omega-3 long-chain polyunsaturated fatty acids (particularly docosahexaenoic acid, DHA), natural pigments, and immunomodulatory polysaccharides. This review synthesizes findings from peer-reviewed studies on the application of microalgae in pet nutrition, covering dogs, cats, and aquatic companion animals. We examine how algal ingredients influence gut microbiota, for instance, by enriching beneficial genera such as Turicibacter and Peptococcus, enhance vaccine responses and mucosal immunity, support cognitive function in aging pets, and contribute to weight management. Particular attention is given to Euglena gracilis and its paramylon (β-1,3-glucan), a pathogen-associated molecular pattern that engages the Dectin-1 pathway to train innate immunity and has demonstrated antiviral activity through host defense mechanisms. The review also surveys the patent landscape, highlighting trends in palatability enhancement, hypoallergenic formulations, and novel delivery formats. Key challenges remain, including ingredient standardization, safety validation, palatability optimization, and consumer acceptance. We outline a translational roadmap that prioritizes well-designed clinical trials in target species and processing methods that preserve bioactivity. Collectively, the evidence positions microalgae, and Euglena gracilis in particular, as promising candidates for next-generation functional pet foods that deliver health benefits alongside ecological sustainability.